Immunic(US:IMUX)2020-03-03 22:08Company Overview - Immunic Therapeutics is developing oral therapies for chronic inflammatory and autoimmune diseases [1, 5] - The company's cash position was $305 million as of September 30, 2019, expected to last into Q1 2021 [8] - Immunic completed a reverse takeover with Vital Therapies, supported by a committed investor base investing approximately $30 million in April 2019 [62] IMU-838 (DHODH Inhibitor) - IMU-838 is currently being tested in three Phase 2 studies [8, 63] - A Phase 2 trial in RRMS enrolled 210 patients across 36 centers in Europe, with top-line data expected in Q3 2020 [23] - Aubagio, another DHODH inhibitor for MS, reached sales of around $18 billion in 2018 [17] - In an investigator-sponsored trial (ENTRANCE) using IMU-838 active moiety, 885% of patients had a total response [33] - The global market for IBD in 2023 is estimated to be approximately $76 billion [67] IMU-935 (Oral IL-17 Inhibitor) - Phase 1 of IMU-935 started in September 2019, with initial data expected in Q1 2020 [63] - IMU-935 inhibits cytokines in the low nanomolar range, with IC50 values of 0005 µM for IL-17A, 0004 µM for IL-17F, and 0003 µM for IFNg [53] IMU-856 (Intestinal Barrier Function) - IMU-856 could be a disruptive technology for treating GI diseases like IBS-D and IBD by restoring intestinal barrier function [63] - Phase 1 single and multiple ascending dose studies for IMU-856 are expected to start in H1 2020 [60]